Glenn Ishioka

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Antonella Vitiello, Glenn Ishioka, H M Grey et al. · Journal of Clinical Investigation · 1995 · 334 citations · Full text

cDNA cloning and immunological characterization of the rye grass allergen Lol p I.

Mary Perez, Glenn Ishioka, L E Walker et al. · Journal of Biological Chemistry · 1990 · 174 citations · Full text

MHC interaction and T cell recognition of carbohydrates and glycopeptides

Glenn Ishioka, Alan Lamont, David Thomson et al. · The Journal of Immunology · 1992 · 168 citations · Full text

Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes

Glenn Ishioka, John Fikes, Gary Hermanson et al. · The Journal of Immunology · 1999 · 163 citations · Full text

Histocompatibility, Mhc Class, Hla Immunogenetics +19

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

Marc Gurwith, Michael Lock, Eve M. Taylor et al. · The Lancet Infectious Diseases · 2013 · 154 citations · Full text